Clinical significance of the molecular detection of melanoma cells circulating in the peripheral blood in melanoma patients

K Konstantopoulos, Maria Psatha, V Kalotychou, N Frangia, I Ioannovits, I Meletis, D Loukopoulos

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: Blood circulating melanoma cells may be important for the spread of the disease. The current methods are not sensitive in detecting micro metastases. Tyrosinase mRNA can be detected in peripheral blood by a molecular test. As tyrosinase is expressed only in melanocytes and melanocytes normally do not circulate in the blood, the test may prove reliable in detecting circulating melanoma cells. METHODS: Experimental design: we used a reverse-transcription polymerase chain reaction (RT-PCR) detecting tyrosinase mRNA in the blood. A prospective investigation in melanoma patients undergoing surgery was conducted; follow-up duration was 12 months. Setting: University Department Laboratory and Melanoma Clinic of a Tertiary Hospital. Patients: a total of 27 Greek patients with a diagnosis of malignant melanoma at different stages of the disease; 12 months follow-up after surgery. Samples form 12 healthy volunteers and 13 patients with chronic myelogenous leukemia served as controls. Interventions: none. Measures: none. RESULTS: We detected mRNA tyrosinase in the peripheral blood in 16 out of 27 melanoma patients studied. No tyrosinase mRNA was detected in any of the 25 samples from the controls. Two of the 16 positive cases developed a metastasis within the next 12 months following testing. The other 14 positive cases remain metastasis free for this period, as also did the test negative cases. CONCLUSIONS: Detection of blood circulating melanoma cells by a RT-PCR technique, may be helpful in defining melanoma patients who are at risk for the spread of the disease.
Original languageEnglish
Pages (from-to)109-113
Number of pages5
JournalPanminerva Medica
Volume43
Issue number2
Publication statusPublished - 1 Jun 2001

Fingerprint

Melanoma
Monophenol Monooxygenase
Messenger RNA
Melanocytes
Neoplasm Metastasis
Reverse Transcription
Polymerase Chain Reaction
Hematologic Tests
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tertiary Care Centers
Healthy Volunteers
Research Design

Keywords

  • Adult
  • Aged
  • Female
  • Humans
  • Leukemia, Myeloid, Acute
  • Male
  • Melanoma
  • Middle Aged
  • Monophenol Monooxygenase
  • Neoplastic Cells, Circulating
  • RNA, Messenger
  • Reference Values
  • Reverse Transcriptase Polymerase Chain Reaction

Cite this

Konstantopoulos, K., Psatha, M., Kalotychou, V., Frangia, N., Ioannovits, I., Meletis, I., & Loukopoulos, D. (2001). Clinical significance of the molecular detection of melanoma cells circulating in the peripheral blood in melanoma patients. Panminerva Medica, 43(2), 109-113.

Clinical significance of the molecular detection of melanoma cells circulating in the peripheral blood in melanoma patients. / Konstantopoulos, K; Psatha, Maria; Kalotychou, V; Frangia, N; Ioannovits, I; Meletis, I; Loukopoulos, D.

In: Panminerva Medica, Vol. 43, No. 2, 01.06.2001, p. 109-113.

Research output: Contribution to journalArticle

Konstantopoulos, K, Psatha, M, Kalotychou, V, Frangia, N, Ioannovits, I, Meletis, I & Loukopoulos, D 2001, 'Clinical significance of the molecular detection of melanoma cells circulating in the peripheral blood in melanoma patients', Panminerva Medica, vol. 43, no. 2, pp. 109-113.
Konstantopoulos K, Psatha M, Kalotychou V, Frangia N, Ioannovits I, Meletis I et al. Clinical significance of the molecular detection of melanoma cells circulating in the peripheral blood in melanoma patients. Panminerva Medica. 2001 Jun 1;43(2):109-113.
Konstantopoulos, K ; Psatha, Maria ; Kalotychou, V ; Frangia, N ; Ioannovits, I ; Meletis, I ; Loukopoulos, D. / Clinical significance of the molecular detection of melanoma cells circulating in the peripheral blood in melanoma patients. In: Panminerva Medica. 2001 ; Vol. 43, No. 2. pp. 109-113.
@article{d5aa650d0773457d94affa11e341478c,
title = "Clinical significance of the molecular detection of melanoma cells circulating in the peripheral blood in melanoma patients",
abstract = "BACKGROUND: Blood circulating melanoma cells may be important for the spread of the disease. The current methods are not sensitive in detecting micro metastases. Tyrosinase mRNA can be detected in peripheral blood by a molecular test. As tyrosinase is expressed only in melanocytes and melanocytes normally do not circulate in the blood, the test may prove reliable in detecting circulating melanoma cells. METHODS: Experimental design: we used a reverse-transcription polymerase chain reaction (RT-PCR) detecting tyrosinase mRNA in the blood. A prospective investigation in melanoma patients undergoing surgery was conducted; follow-up duration was 12 months. Setting: University Department Laboratory and Melanoma Clinic of a Tertiary Hospital. Patients: a total of 27 Greek patients with a diagnosis of malignant melanoma at different stages of the disease; 12 months follow-up after surgery. Samples form 12 healthy volunteers and 13 patients with chronic myelogenous leukemia served as controls. Interventions: none. Measures: none. RESULTS: We detected mRNA tyrosinase in the peripheral blood in 16 out of 27 melanoma patients studied. No tyrosinase mRNA was detected in any of the 25 samples from the controls. Two of the 16 positive cases developed a metastasis within the next 12 months following testing. The other 14 positive cases remain metastasis free for this period, as also did the test negative cases. CONCLUSIONS: Detection of blood circulating melanoma cells by a RT-PCR technique, may be helpful in defining melanoma patients who are at risk for the spread of the disease.",
keywords = "Adult, Aged, Female, Humans, Leukemia, Myeloid, Acute, Male, Melanoma, Middle Aged, Monophenol Monooxygenase, Neoplastic Cells, Circulating, RNA, Messenger, Reference Values, Reverse Transcriptase Polymerase Chain Reaction",
author = "K Konstantopoulos and Maria Psatha and V Kalotychou and N Frangia and I Ioannovits and I Meletis and D Loukopoulos",
year = "2001",
month = "6",
day = "1",
language = "English",
volume = "43",
pages = "109--113",
journal = "Panminerva Medica",
issn = "0031-0808",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Clinical significance of the molecular detection of melanoma cells circulating in the peripheral blood in melanoma patients

AU - Konstantopoulos, K

AU - Psatha, Maria

AU - Kalotychou, V

AU - Frangia, N

AU - Ioannovits, I

AU - Meletis, I

AU - Loukopoulos, D

PY - 2001/6/1

Y1 - 2001/6/1

N2 - BACKGROUND: Blood circulating melanoma cells may be important for the spread of the disease. The current methods are not sensitive in detecting micro metastases. Tyrosinase mRNA can be detected in peripheral blood by a molecular test. As tyrosinase is expressed only in melanocytes and melanocytes normally do not circulate in the blood, the test may prove reliable in detecting circulating melanoma cells. METHODS: Experimental design: we used a reverse-transcription polymerase chain reaction (RT-PCR) detecting tyrosinase mRNA in the blood. A prospective investigation in melanoma patients undergoing surgery was conducted; follow-up duration was 12 months. Setting: University Department Laboratory and Melanoma Clinic of a Tertiary Hospital. Patients: a total of 27 Greek patients with a diagnosis of malignant melanoma at different stages of the disease; 12 months follow-up after surgery. Samples form 12 healthy volunteers and 13 patients with chronic myelogenous leukemia served as controls. Interventions: none. Measures: none. RESULTS: We detected mRNA tyrosinase in the peripheral blood in 16 out of 27 melanoma patients studied. No tyrosinase mRNA was detected in any of the 25 samples from the controls. Two of the 16 positive cases developed a metastasis within the next 12 months following testing. The other 14 positive cases remain metastasis free for this period, as also did the test negative cases. CONCLUSIONS: Detection of blood circulating melanoma cells by a RT-PCR technique, may be helpful in defining melanoma patients who are at risk for the spread of the disease.

AB - BACKGROUND: Blood circulating melanoma cells may be important for the spread of the disease. The current methods are not sensitive in detecting micro metastases. Tyrosinase mRNA can be detected in peripheral blood by a molecular test. As tyrosinase is expressed only in melanocytes and melanocytes normally do not circulate in the blood, the test may prove reliable in detecting circulating melanoma cells. METHODS: Experimental design: we used a reverse-transcription polymerase chain reaction (RT-PCR) detecting tyrosinase mRNA in the blood. A prospective investigation in melanoma patients undergoing surgery was conducted; follow-up duration was 12 months. Setting: University Department Laboratory and Melanoma Clinic of a Tertiary Hospital. Patients: a total of 27 Greek patients with a diagnosis of malignant melanoma at different stages of the disease; 12 months follow-up after surgery. Samples form 12 healthy volunteers and 13 patients with chronic myelogenous leukemia served as controls. Interventions: none. Measures: none. RESULTS: We detected mRNA tyrosinase in the peripheral blood in 16 out of 27 melanoma patients studied. No tyrosinase mRNA was detected in any of the 25 samples from the controls. Two of the 16 positive cases developed a metastasis within the next 12 months following testing. The other 14 positive cases remain metastasis free for this period, as also did the test negative cases. CONCLUSIONS: Detection of blood circulating melanoma cells by a RT-PCR technique, may be helpful in defining melanoma patients who are at risk for the spread of the disease.

KW - Adult

KW - Aged

KW - Female

KW - Humans

KW - Leukemia, Myeloid, Acute

KW - Male

KW - Melanoma

KW - Middle Aged

KW - Monophenol Monooxygenase

KW - Neoplastic Cells, Circulating

KW - RNA, Messenger

KW - Reference Values

KW - Reverse Transcriptase Polymerase Chain Reaction

M3 - Article

VL - 43

SP - 109

EP - 113

JO - Panminerva Medica

JF - Panminerva Medica

SN - 0031-0808

IS - 2

ER -